Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines

Craven RA, Stanley AJ, Hanrahan S, Totty N, Jackson DP, Popescu R, Taylor A, Frey J, Selby PJ, Patel PM, Banks RE (2004)
PROTEOMICS 4(12): 3998-4009.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ;
Abstract
Treatment of patients with malignant melanoma with interferon-alpha achieves a response in a small but significant subset of patients. Currently, although much is known about interferon biology, little is known about either the particular mechanisms of interferon-alpha activity that are crucial for response or why only some patients respond to interferon-alpha therapy. Two melanoma cell lines (MeWo and MM418) that are known to differ in their response to the antiproliferative activity of interferon-alpha, have been used as a model system to investigate interferon-alpha action. Using a proteomics approach based on two-dimensional polyacrylamide gel electrophoresis and mass spectrometry, several proteins induced in response to interferon-alpha have been identified. These include a number of gene products previously known to be type I interferon responsive (tryptophanyl tRNA synthetase, leucine aminopeptidase, ubiquitin cross-reactive protein, gelsolin, FUSE binding protein 2 and hPNPase) as well as a number of proteins not previously reported to be induced by type I interferon (cathepsin B, proteasomal activator 28alpha and alpha-SNAP). Although the proteins upregulated by interferon-alpha were common between the cell lines when examined at the level of Western blotting, the disparity in the basal level of cathepsin B was striking, raising the possibility that the higher level in MM418 may contribute to the sensitivity of this cell line to interferon-alpha treatment.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Craven RA, Stanley AJ, Hanrahan S, et al. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS. 2004;4(12):3998-4009.
Craven, R. A., Stanley, A. J., Hanrahan, S., Totty, N., Jackson, D. P., Popescu, R., Taylor, A., et al. (2004). Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS, 4(12), 3998-4009.
Craven, R. A., Stanley, A. J., Hanrahan, S., Totty, N., Jackson, D. P., Popescu, R., Taylor, A., Frey, J., Selby, P. J., Patel, P. M., et al. (2004). Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS 4, 3998-4009.
Craven, R.A., et al., 2004. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS, 4(12), p 3998-4009.
R.A. Craven, et al., “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines”, PROTEOMICS, vol. 4, 2004, pp. 3998-4009.
Craven, R.A., Stanley, A.J., Hanrahan, S., Totty, N., Jackson, D.P., Popescu, R., Taylor, A., Frey, J., Selby, P.J., Patel, P.M., Banks, R.E.: Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS. 4, 3998-4009 (2004).
Craven, RA, Stanley, AJ, Hanrahan, S, Totty, N, Jackson, DP, Popescu, R, Taylor, A, Frey, Jürgen, Selby, PJ, Patel, PM, and Banks, RE. “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines”. PROTEOMICS 4.12 (2004): 3998-4009.
This data publication is cited in the following publications:
This publication cites the following data publications:

9 Citations in Europe PMC

Data provided by Europe PubMed Central.

Protein signatures for survival and recurrence in metastatic melanoma.
Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM., J Proteomics 74(7), 2011
PMID: 21549228
Cancer biomarker discovery: the entropic hallmark.
Berretta R, Moscato P., PLoS ONE 5(8), 2010
PMID: 20805891
Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.
Pincelli C, Pignatti M, Borroni RG., Exp. Dermatol. 18(4), 2009
PMID: 19348000
Identification and functional validation of therapeutic targets for malignant melanoma.
Gremel G, Rafferty M, Lau TY, Gallagher WM., Crit. Rev. Oncol. Hematol. 72(3), 2009
PMID: 19328713
In vitro and in vivo effect of IFNalpha on B16F10 melanoma in two models: subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice).
Martinez Conesa C, Alvarez Sanchez N, Vicente Ortega V, Garcia Reverte J, Pascual Carpe F, Campos Aranda M., Biomed. Pharmacother. 63(4), 2009
PMID: 19171452
Toxicogenomics of A375 human malignant melanoma cells.
Cheng SL, Huang-Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ., Pharmacogenomics 8(8), 2007
PMID: 17716235
Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
Timar J, Meszaros L, Ladanyi A, Puskas LG, Raso E., Cell. Immunol. 244(2), 2006
PMID: 17433276
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.
Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS, Borden EC, Li J, Virgin HW, Zhang DE., Biochem. Biophys. Res. Commun. 336(2), 2005
PMID: 16139798

67 References

Data provided by Europe PubMed Central.

Study of the development of chemoresistance in melanoma cell lines using proteome analysis.
Sinha P, Poland J, Kohl S, Schnolzer M, Helmbach H, Hutter G, Lage H, Schadendorf D., Electrophoresis 24(14), 2003
PMID: 12874874
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect.
Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE., Proteomics 3(8), 2003
PMID: 12923786
Differential expression of the liver proteome in senescence accelerated mice.
Cho YM, Bae SH, Choi BK, Cho SY, Song CW, Yoo JK, Paik YK., Proteomics 3(10), 2003
PMID: 14625850
Interferons: mechanisms of action and clinical applications.
Parmar S, Platanias LC., Curr Opin Oncol 15(6), 2003
PMID: 14624225
Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma.
Jakschies D, Hochkeppel HK, Horisberger MA, Deicher H, von Wussow P., J. Invest. Dermatol. 95(6 Suppl), 1990
PMID: 1701809
Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.
Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, Orfanos CE., J. Invest. Dermatol. 95(6 Suppl), 1990
PMID: 2124247
Study of therapy resistance in cancer cells with functional proteome analysis.
Poland J, Schadendorf D, Lage H, Schnolzer M, Celis JE, Sinha P., Clin. Chem. Lab. Med. 40(3), 2002
PMID: 12005211
Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma.
Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G., Cancer 91(5), 2001
PMID: 11251949
A unique set of polypeptides is induced by gamma interferon in addition to those induced in common with alpha and beta interferons.
Weil J, Epstein CJ, Epstein LB, Sedmak JJ, Sabran JL, Grossberg SE., Nature 301(5899), 1983
PMID: 6218412
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY., Science 272(5262), 1996
PMID: 8614832
Lack of p21waf1 and p27kip1 protein induction by interferon-??2a in human melanoma cell lines
Bearzatto, Melanoma Research 9(5), 1999
Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW., J. Natl. Cancer Inst. 84(15), 1992
PMID: 1378904
Interferons in melanoma.
Agarwala SS, Kirkwood JM., Curr Opin Oncol 8(2), 1996
PMID: 8727310

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 15449380
PubMed | Europe PMC

Search this title in

Google Scholar